Year: 2026

70,954 sell orders completed January 1 through March 15, up 14.2% year-over-year; 25,508 first-time sellers onboarded in Q1 2026, up 18.5%, as CardCash accelerates marketplace supply ahead of spring demand season SCHAUMBURG, IL, March 30, 2026 (GLOBE NEWSWIRE) — Giftify, Inc. (NASDAQ: GIFT) (the “Company”), the owner and operator of CardCash.com, Restaurant.com, and Takeout7.com, and a leader in the incentives and rewards industry, today announced preliminary sell-side performance results for CardCash.com for the period January 1 through March 15, 2026, reflecting accelerating growth in both seller order volume and new seller acquisition as the platform expands its supply base ahead of the spring buying season. The sell side of CardCash’s marketplace refers to consumers and businesses who sell their unwanted gift cards to CardCash...

Company Advances Strategic Transformation into an AI-Driven Intelligent Energy Platform and Provides 2026 Outlook VALENCIA, Spain, March 30, 2026 (GLOBE NEWSWIRE) — Mariano Soria, Chief Executive Officer of Turbo Energy S.A. (Nasdaq: TURB) (“Turbo Energy” or the “Company”), a global provider of AI-optimized solar energy storage technologies and solutions, today issued a shareholder update highlighting preliminary, unaudited revenue results for fiscal year 2025 with expected revenue in the range of $22.5 million and $23.5 million (€19.5 million – €20.4 million), representing 130%-140% year-over-year growth compared to fiscal year 2024 as Turbo Energy advances its strategic transformation into an AI-driven intelligent energy solutions platform. Soria stated: “Fiscal year 2025 marked a decisive financial and strategic inflection...

Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the second patient in the second cohort (fifth patient overall) in its Phase 1 CER-1236 clinical trial in hematologic malignancies, including acute myeloid leukemia (AML), with planned expansion into myelodysplastic syndromes (MDS) and myelofibrosis (MF).   With more than seven days of follow-up completed after the second patient’s infusion, protocol-defined monitoring of safety, pharmacokinetic, pharmacodynamic, and clinical...

LAS VEGAS, NV, March 30, 2026 (GLOBE NEWSWIRE) — Eva Live Inc. (NASDAQ: GOAI), a high-growth AI-driven digital advertising and marketing technology company, today announced that it has engaged Anderson Kill P.C. to actively support the Company’s execution of a strategic initiative to align GOAI with Nasdaq’s newly announced tokenization framework. The Anderson Kill P.C. team is led by Louis L. Nock, a Shareholder of the firm and former New York State Supreme Court Justice who concentrates on the emerging legal, regulatory, and corporate aspects of Digital Assets and Blockchain Technology. Nasdaq’s introduction of tokenized securities trading marks a transformative shift in global capital markets, enabling blockchain-based settlement, expanded investor access, and the potential for extended or 24/7 trading environments. As a Nasdaq-listed...

Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the year ended December 31, 2025. 2025 Financial Highlights Compared to 2024:Net revenue increased 216% to $431,609 from $136,643Gross Margin Expanded by 7,240 Basis Points to 76.8%Excluding a one-time, non-cash impairment charge of $26.3 million, net loss from continuing operations improved by approximately $37,000 year-over-yearAs...

Data presented at ACC.26 demonstrate a high prevalence of clinically actionable arrhythmias across CKM patient populations using the Zio® ambulatory ECG portfolio.1,2 Chief Medical Officer Mintu Turakhia, MD, MS, delivered the 57th Annual Louis F. Bishop Keynote on scaling AI in cardiology and translating advances into clinical practice. iRhythm Academy launch expands access to clinician education at scale in ambulatory cardiac monitoring as the field continues to advance.SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) — iRhythm Holdings, Inc. (NASDAQ: IRTC) announced results from three retrospective analyses presented at the American College of Cardiology (ACC) 2026 Annual Scientific Sessions in New Orleans, March 28–30, 2026, that add to the growing body of clinical evidence supporting the benefits of its Zio® ambulatory ECG...

DENVER, March 30, 2026 (GLOBE NEWSWIRE) — American Rare Earths (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) (“ARR” or the “Company”) is pleased to announce that it has engaged Tetra Tech, a U.S. based major consulting and engineering services company, to complete an Oxides to Metals study for the Company’s heavy rare earths (“HREE”) stream. The study will evaluate options to convert separated heavy rare earth oxides from the American Rare Earths Halleck Creek Project in Wyoming all the way to metal, a critical midstream step immediately preceding the manufacture of permanent magnets relied upon by defense and advanced technology sectors. Positioning into the U.S. midstream Today, China dominates the midstream of the rare earth value chain, including oxide separation and metal production. The United States has prioritized development of...

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions. Teva’s proposed biosimilar candidate to Xolair® (omalizumab) is accepted for review by U.S. FDA and EU EMA. These milestones demonstrate Teva’s biosimilars expertise and are a significant step in Teva’s Pivot to Growth strategy, highlighting its transformation into a leading biopharmaceutical company with a broad biosimilars portfolio.TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demonstrating continued momentum in the advancement of its Pivot to Growth strategy. The United States (U.S.) Food and Drug Administration...

Using its pioneering AI-platform, AI-Immunology™, Evaxion has, in collaboration with the Gates Foundation, developed novel design concepts for polio vaccines potentially superior to those currently used The AI-Immunology™ concepts include hybrid capsid designs and de novo designed B-cell antigen approaches Despite polio vaccines being available for decades, the highly infectious viral disease continues to pose a global health risk Evaxion will also present data from its EVX-V1 vaccine program targeting cytomegalovirus at the World Vaccine CongressCOPENHAGEN, Denmark, March 30, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has in collaboration with the Gates Foundation developed novel and potentially superior...